Clinical Trial Update: Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1, first-in-human dose-finding and expansion study of XmAb808 in combination with pembrolizumab in advanced solid tumors; the trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Clear Cell Renal Cell Carcinoma
• Cutaneous Melanoma
• Epithelial Ovarian Cancer
• Head and Neck Squamous Cell Carcinoma
• Non-small Cell Lung Cancer
• Triple-negative Breast Cancer
• Urothelial Carcinoma

Drugs mentioned

• Pembrolizumab (pembrolizumab)
• XmAb808

Snippet

Sponsor: Xencor, Inc. | Conditions: Head and Neck Squamous Cell Carcinoma, Melanoma Excluding Uveal Melanoma | Phase 1 | Status: COMPLETED